Regeneron Pharmaceuticals, Inc.

In its 13F for Q1 2026 (holdings as of March 31, 2026, filed May 8, 2026), Regeneron Pharmaceuticals, Inc. reported 2 stock positions worth $47.9 million. Its top holding was Intellia Therapeutics (NTLA) at 99.1% of the portfolio, followed by Adicet Bio (ACET, 0.9%). Its holdings were unchanged from Q4 2025.

Most Recent 13F
Q2 2026
Location
TARRYTOWN, NY
CIK
0000872589
Portfolio Value
$47.9M (Q1 2026)
SEC Filing
0001104659-26-057922 ↗ filed May 8, 2026

Holdings Value

0$500.0M$1.0B$1.5B Q4 2024: $1.1B Q4 2024 Q1 2025: $1.2B Q1 2025 Q2 2025: $1.5B Q2 2025 Q3 2025: $700.4M Q3 2025 Q4 2025: $33.8M Q4 2025 Q1 2026: $47.9M $47.9M Q1 2026 Q2 2026: $177.2M Q2 2026

Holdings 2 stocks · $47.9M
NTLA Intellia Therapeutics Inc. 99.14% 3,702,995 $47.5M No change
ACET Adicet Bio Inc. 0.86% 60,511 $412K No change

Portfolio Sells Q4 2025 → Q1 2026
None this quarter.

Portfolio Buys Q4 2025 → Q1 2026
None this quarter.

All Filings

QuarterPositions13F Reported ValueTop Holdings
Q2 2026 3$177.2MPBLS, NTLA, ACET
Q1 2026 2$47.9MNTLA, ACET
Q4 2025 2$33.8MNTLA, ACET
Q3 2025 4$700.4MALNY, NTLA, ADVM, ACET
Q2 2025 4$1.5BALNY, NTLA, ACET, ADVM
Q1 2025 6$1.2BALNY, NTLA, TSVT, ADVM, ACET
Q4 2024 6$1.1BALNY, NTLA, TSVT, ACET, ADVM